论文部分内容阅读
类风湿性关节炎部分患者放弃青霉胺(PA)治疗,主要是因为引起蛋白尿。作者研究PA能否在避免发生蛋白尿的低剂量时继续有效。研究对象符合以下条件:在初次治疗中,对PA有良好的临床和实验室疗效,疾病复发时再次要求PA治疗;停服PA后,尿蛋自消失至少维持3个月以上;血清尿素、肝酐、白蛋白均在正常范围,尿镜检无红细胞或管型,纤维蛋白降解物(FDP)排泄正常,已排除PA诱致肾病的可能。方法开始剂量50mg/日,以后每月增加50mg/日至150mg/日,维持4个月。若疾病仍持续活动,
Some patients with rheumatoid arthritis to give penicillamine (PA) treatment, mainly because of proteinuria. The authors investigated whether PA can continue to be effective in preventing low doses of proteinuria. The subjects met the following conditions: In the first treatment, PA has good clinical and laboratory efficacy, relapse of the disease once again required PA treatment; stop taking PA, the urine egg self-disappeared for at least 3 months or more; serum urea, liver Anhydride, albumin are in the normal range, urinary microscopy without erythrocyte or tube type, fibrin degradation (FDP) normal excretion of PA-induced nephropathy has been ruled out. Method start dose 50mg / day, after a monthly increase of 50mg / day to 150mg / day for 4 months. If the disease is still active,